The Biosimilar Patent Dance

A biosimilar applicant has sole control over whether to initiate the “patent dance” under the Biologics Price Competition and Innovation Act of 2009 (BPCIA), and how far to take it.  The question for the biosimilar applicant is how to most effectively leverage that control.  Limin Zheng explores the question in her two-part article published in Biosimilar DevelopmentPart 1: Shall We (Patent) Dance? — Key Considerations For Biosimilar Applicants; Part 2: The Biosimilar Patent Dance: What Can We Learn From Recent BPCIA Litigation?


Leave a Reply

Your email address will not be published. Required fields are marked *